A large study of 133,764 adults found that a voluntary digital lifestyle program reduced 10-year diabetes risk by 45.6% in prediabetics and doubled remission rates in diabetics, with significant ...

Cholesterol-lowering foods can be a helpful addition to your diet, but they aren't a substitute for statins. Here are two of ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Verve shares Phase 1b results of VERVE-102, showing dose-dependent LDL-C reductions and strong safety in patients with HeFH ...

The focus is on a drug called Lepodisiran, that could target certain factors that increase risk of heart attacks and strokes.

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Joseph Saseen, PharmD, discussed the importance of knowing lipoprotein a (Lp[a]) levels to enable clinicians to provide the ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

Eli Lilly has reported promising Phase II results for lepodisiran, its experimental therapy aimed at reducing lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...